Abstract
Objective: This article puts forward various ocular findings and its prevalence in hospitalized patients with confirmed Dengue serology. The aim is to spread awareness about these findings and call for complete eye examination in patients of dengue fever so that the ocular findings are not missed.
Methods: This is a cross-sectional study, conducted on confirmed cases of 112 dengue patients in Dengue isolation ward in a tertiary care hospital, Government Medical College, Patiala, India, during and after the monsoon season.
Results: Various fundus findings in dengue fever seen in our study are Dot blot hemorrhages, cotton wool spots, macular hemorrhages, macular edema, Roth spots, vascular sheathing, hard exudates, and sub-conjunctival hemorrhage. Cumulative prevalence of these findings was 9.82% in hospitalized patients of dengue fever. Blurring of vision was also a common symptom.
Conclusion: Ocular findings do occur in dengue fever, along with other systemic manifestations such as fever, headache, myalgia, arthralgia, retro-orbital pain, hemorrhagic fever, and shock syndrome. Ocular examination should be undertaken in all patients with dengue fever so that these findings are not missed. Further studies are needed to ascertain its pathophysiology.
Publisher
Innovare Academic Sciences Pvt Ltd
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology
Reference15 articles.
1. National Guidelines Dengue Case Management during COVID-19 Pandemic, By National Vector Borne Disease Control Programme. Directorate General of Health Services, MoHFw, GOI; 2020.
2. Rahman A, Faridi J, Rahman S, Khondokar AI, Naz B, Hossain MM. Dengue: An emerging ocular problem. Clin Ophthalmol 2021;4:201-6.
3. Park K. Park’s Textbook of Preventive and Social Medicine. ???: ???; ???.
4. Guidelines for Clinical Management of Dengue Fever, Dengue Hemorrhagic Fever and Dengue Shock Syndrome. NVBDCP, DGHS, MoHFw, GOI; 2008.
5. Latif N, Kowsigan M, Jyotirmay B, Dutta MP. Dengue-associated eye disease. Nepal J Ophthalmol 2019;11:115-21.